HUT78055A - IL-5 Mediált rendellenességek kezelésére használható rekombináns IL-5 antagonisták - Google Patents

IL-5 Mediált rendellenességek kezelésére használható rekombináns IL-5 antagonisták

Info

Publication number
HUT78055A
HUT78055A HU9901120A HU9901120A HUT78055A HU T78055 A HUT78055 A HU T78055A HU 9901120 A HU9901120 A HU 9901120A HU 9901120 A HU9901120 A HU 9901120A HU T78055 A HUT78055 A HU T78055A
Authority
HU
Hungary
Prior art keywords
treatment
pct
recombinant
mediated disorders
antagonists useful
Prior art date
Application number
HU9901120A
Other languages
English (en)
Other versions
HU222992B1 (hu
Inventor
Robert S. Ames
Edward Robert Appelbaum
Irwin M. Chaiken
Richard M. Cook
Mitchell Stuart Gross
Stephen Dudley Holmes
Lynette Jane Mcmillan
Timothy Wayne Theisen
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham Plc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27408594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUT78055(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/467,420 external-priority patent/US5683892A/en
Application filed by Smithkline Beecham Corporation, Smithkline Beecham Plc. filed Critical Smithkline Beecham Corporation
Publication of HUT78055A publication Critical patent/HUT78055A/hu
Publication of HU222992B1 publication Critical patent/HU222992B1/hu
Priority to HUS1500070C priority Critical patent/HUS1500070I1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
HU9901120A 1994-12-23 1995-12-22 IL-5 Mediált rendellenességek kezelésére használható rekombináns IL-5 antagonisták HU222992B1 (hu)

Priority Applications (1)

Application Number Priority Date Filing Date Title
HUS1500070C HUS1500070I1 (hu) 1994-12-23 2015-12-17 IL-5-Mediált rendellenességek kezelésére használható rekombináns IL-5 antagonisták

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36313194A 1994-12-23 1994-12-23
US08/467,420 US5683892A (en) 1994-12-23 1995-06-06 DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/470,110 US5693323A (en) 1994-12-23 1995-06-06 Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
PCT/US1995/017082 WO1996021000A2 (en) 1994-12-23 1995-12-22 Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders

Publications (2)

Publication Number Publication Date
HUT78055A true HUT78055A (hu) 1999-07-28
HU222992B1 HU222992B1 (hu) 2004-01-28

Family

ID=27408594

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9901120A HU222992B1 (hu) 1994-12-23 1995-12-22 IL-5 Mediált rendellenességek kezelésére használható rekombináns IL-5 antagonisták

Country Status (22)

Country Link
US (1) US6129913A (hu)
EP (1) EP0800536B1 (hu)
JP (2) JP2001523083A (hu)
CN (1) CN100391977C (hu)
AT (1) ATE346867T1 (hu)
AU (1) AU708951B2 (hu)
BR (1) BR9510499B1 (hu)
CA (1) CA2208503C (hu)
CZ (1) CZ297045B6 (hu)
DE (1) DE69535319T2 (hu)
DK (1) DK0800536T3 (hu)
ES (1) ES2277336T3 (hu)
FI (1) FI119374B (hu)
HK (1) HK1003651A1 (hu)
HU (1) HU222992B1 (hu)
LU (1) LU92912I2 (hu)
MX (1) MX9704779A (hu)
NL (1) NL300787I2 (hu)
NO (2) NO324181B1 (hu)
NZ (1) NZ301916A (hu)
PL (1) PL194312B1 (hu)
WO (1) WO1996021000A2 (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
ES2568898T3 (es) 1999-04-09 2016-05-05 Kyowa Hakko Kirin Co., Ltd. Procedimiento para controlar la actividad de una molécula inmunofuncional
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DK1527100T3 (da) * 2002-03-29 2009-09-07 Schering Corp Humane monoklonale antistoffer mod interleukin-5 og fremgangsm der og sammens tninger omfattende samme
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
US20070219117A1 (en) * 2003-10-27 2007-09-20 Medvet Science Pty Ltd Bidentate motif and methods of use
AU2005297803B2 (en) * 2004-10-28 2011-06-16 Kyowa Hakko Kirin Co., Ltd. Remedy for endometriosis
US20100086547A1 (en) 2007-04-30 2010-04-08 Smithkline Beecham Corporation Methods for administering anti-il-5 antibodies
JP4335286B2 (ja) 2008-02-08 2009-09-30 ファナック株式会社 部品保護機能を備えたロボット制御装置及びロボット制御方法
CN102026660A (zh) 2008-03-28 2011-04-20 葛兰素史密斯克莱有限责任公司 治疗方法
WO2011094259A2 (en) * 2010-01-28 2011-08-04 Glaxo Group Limited Cd127 binding proteins
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
KR20240099511A (ko) 2015-08-24 2024-06-28 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
US11046782B2 (en) * 2016-03-30 2021-06-29 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein A repetitions predominant (GARP) and for providing effective immunotherapy alone or in combination
CA3048186A1 (en) 2016-12-23 2018-06-28 Cephalon, Inc. Anti-il-5 antibodies
PE20191844A1 (es) * 2017-05-26 2019-12-31 Glaxosmithkline Ip Dev Ltd Composiciones biofarmaceuticas y metodos relacionados
BR112020005766A2 (pt) * 2017-09-29 2020-10-13 Jiangsu Hengrui Medicine Co., Ltd. anticorpo il-5, fragmento de ligação ao antígeno do mesmo, e aplicação médica do mesmo
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
EP3896085A4 (en) * 2018-12-12 2022-11-30 Shanghai Pharmaexplorer Co., Ltd. MONOCLONAL ANTIBODY TO HUMAN INTERLEUKIN 5 (IL-5) AND ITS USE
JP2022528230A (ja) * 2019-03-29 2022-06-09 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ｉｌ－５に対する抗体を含有する医薬組成物及びその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
ES2062032T3 (es) * 1988-11-03 1994-12-16 Schering Corp Antagonista de interleuquina-5 para prevenir o reducir la eosinofilia.
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ZA929328B (en) * 1991-12-02 1993-07-20 Fluor Corp Apparatus and method for economic use of excess compressed air when firing low caloric-value gas in a combustion gas turbine.
RU94045919A (ru) * 1992-02-06 1996-11-10 Шеринг Корпорейшн (US) Антитела, клетки, полипептид, днк векторы, способ получения полипептида, способ получения антитела, фармацевтическая композиция
JPH06141885A (ja) * 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
AU1289795A (en) * 1993-11-19 1995-06-06 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US5783184A (en) * 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
WO2001012646A1 (en) * 1999-08-19 2001-02-22 Smithkline Beecham Corporation Sialoadhesin factor-1 agonist and antagonist antibodies

Also Published As

Publication number Publication date
BR9510499B1 (pt) 2009-05-05
US6129913A (en) 2000-10-10
FI972703A0 (fi) 1997-06-23
CA2208503C (en) 2009-12-01
JP2001523083A (ja) 2001-11-20
BR9510499A (pt) 1999-03-30
ATE346867T1 (de) 2006-12-15
AU4745096A (en) 1996-07-24
CN1175263A (zh) 1998-03-04
NL300787I1 (hu) 2016-04-05
NO972913D0 (no) 1997-06-20
MX9704779A (es) 1997-09-30
JP2008029355A (ja) 2008-02-14
DK0800536T3 (da) 2007-04-02
LU92912I2 (fr) 2016-02-16
FI972703A (fi) 1997-08-22
CZ196397A3 (en) 1997-10-15
HU222992B1 (hu) 2004-01-28
AU708951B2 (en) 1999-08-19
NO2015027I2 (no) 2016-01-04
NO972913L (no) 1997-08-19
PL194312B1 (pl) 2007-05-31
DE69535319D1 (de) 2007-01-11
HK1003651A1 (en) 1998-11-06
ES2277336T3 (es) 2007-07-01
EP0800536A4 (en) 2004-12-01
NZ301916A (en) 1999-05-28
WO1996021000A2 (en) 1996-07-11
DE69535319T2 (de) 2007-07-19
CA2208503A1 (en) 1996-07-11
CZ297045B6 (cs) 2006-08-16
WO1996021000A3 (en) 1996-09-06
EP0800536B1 (en) 2006-11-29
NO324181B1 (no) 2007-09-03
FI119374B (fi) 2008-10-31
EP0800536A2 (en) 1997-10-15
NL300787I2 (hu) 2016-04-05
CN100391977C (zh) 2008-06-04
PL321088A1 (en) 1997-11-24
NO2015027I1 (no) 2015-12-18

Similar Documents

Publication Publication Date Title
NL300787I2 (hu)
MY124219A (en) Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders
MX9702932A (es) L-ribofuranosilnucleosidos.
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
ZA953537B (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
UA48940C2 (uk) Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
GB9204414D0 (en) Method of treatment
IL114598A (en) Triazole compounds their preparation and pharmaceutical compositions containing them
DE69413829D1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
DE69911401D1 (en) Immunoregulator
IL117209A (en) 1-aryl-2-acylamino-ethane compounds and pharmaceutical compositions containing them
GB8900812D0 (en) Pharmaceutical method and compositions
MX9702926A (es) L-eritrosilnucleosidos.
HUT77868A (hu) Imidazopiridin-azolidinonok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra
IL122659A (en) Pharmaceutical compositions for the treatment of dyspeptic symptoms comprising angiotensin ii type receptor antagonists
GB9516073D0 (en) Pharmaceutical composition
MX9702927A (es) L-piranosilnucleosidos.
GB9015774D0 (en) Novel treatment
MXPA01010449A (es) Composicion y metodo util para el tratamiento del colico.
MY129421A (en) INHIBITORS OF p38
ATE318612T1 (de) Methoden und zusammensetzungen zur behandlung der hyperlipidämie

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20031127

GB9A Succession in title

Owner name: GLAXOSMITHKLINE LLC, US

Free format text: FORMER OWNER(S): SMITHKLINE BEECHAM CORPORATION, US; SMITHKLINE BEECHAM PLC., GB

AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: MEPOLIZUMAB; REGISTRATION NO/DATE: EU/1/15/1043 20151207

Spc suppl protection certif: S1500070

Filing date: 20151217

Expiry date: 20151222

FG4S Grant of supplementary protection certificate

Spc suppl protection certif: S1500070

Filing date: 20151217

Expiry date: 20151222